WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

August 24, 2005 12:01 ET

WEX to Present two Posters at the 11th World Congress on Pain

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 24, 2005) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that Dr. Kim Fisher, Senior Research Scientist for WEX, is presenting two posters at the 11th World Congress on Pain being held this week in Sydney, Australia.

Today, Dr. Fisher presented further details of the tolerability and safety of intramuscular tetrodotoxin (TTX) in patients with severe cancer pain. The results demonstrate that four-day treatment of intramuscular TTX is safe and well tolerated at doses up to and including 30 micrograms (twice daily) in patients who are taking opioids and other medications for their pain. At these dosages, ninety-eight percent (98%) of the adverse events were mild or moderate and did not raise specific safety concerns.

On the 26th of August, Dr. Fisher will propose a novel approach for assessing the pain relieving effects of new analgesic drugs in clinical trials and will be reporting that TTX treatment can produce long-lasting relief of severe refractory cancer pain. Dr. Fisher stated, "The pain relieving properties of TTX are unusual. For some patients with severe pain problems TTX produces relief of pain for a period of time that extends well beyond the treatment period. Since TTX has a very selective mechanism of action, clinical experience with this compound had the potential to substantially improve pain researchers' understanding of the neural basis of clinical pain syndromes."

The International Association for the Study of Pain (IASP) is expecting to draw 5500 medical professionals from around the world to take part in this prestigious conference which is held every three years. The scientific program of the conference is intended to provide delegates with an overview of the state-of-the-art of a wide range of topics in the areas of acute, chronic, and cancer pain; to provide practical reviews of current research and therapies in these areas; and to enable delegates to participate in formal and informal discussions with international experts.

The Company currently has a Phase IIb/III trial of Tectin™ (derived from TTX) underway in Canada to evaluate the efficacy and safety of a drug for treatment of medically refractory cancer pain.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat moderate to severe acute and chronic pain, symptom pain relief associated with addiction withdrawal from opioid abuse and medicines designed for local anaesthesia. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information

  • WEX Pharmaceuticals Inc.
    Don Evans
    (604) 683-8880 or Toll Free: 1-800-722-7549
    WEX Pharmaceuticals Inc.
    Gordon Stanley
    Corporate Communications
    (604) 683-8880 or Toll Free: 1-800-722-7549
    (604) 683-8868 (FAX)